▟ Vinebot intrinsic value, daily

← back

IDXX Idexx Laboratories

healthcare · valued with opus medium conviction · deep-dived 2026-11-02

HOLD
Intrinsic value$325.07
Price (at call)$551.21
Margin of safety -41.0%
vs market (rating basis) -4.4%

A best-in-class vet diagnostics moat, but the price assumes more growth than the franchise likely delivers.

The story

IDEXX is the dominant global franchise in companion-animal diagnostics. It runs a razor/razorblade model in which a large installed base of in-clinic analyzers drives high-margin, recurring consumables, reference-lab and software revenue (over 90% recurring). Its moat comes from switching costs, its installed-base scale and its integrated cloud software. Pet ownership trends and rising diagnostic intensity per vet visit keep the reinvestment runway long. IDEXX is a mature but still compounding franchise: growth has slowed from post-COVID highs to high single digits because vet visit volumes are soft, while pricing and new platforms (inVue Dx, Cancer Dx) offset that softness.

Year-1 growth of about 9.5% combines mid-single-digit price increases, installed-base expansion and new menu items against flat to declining clinic visits. It sits slightly above the 5-year CAGR because of the inVue and Cancer Dx launches. Margins drift up from 32% to 34% through operating leverage on consumables and software, not beyond. Incremental sales-to-capital of 2.5 exceeds the historical 1.86 because growth is now consumables-led and needs less capital. A 13-year horizon fits a durable moat with a long runway, and terminal growth of 4% stays below the 4.93% risk-free rate. The market price still embeds more optimism than these drivers support.

Value drivers

Revenue growth (Y1)9.5%
Terminal growth4.0%
Forecast horizon13y
Target operating margin34.0%
Years to target margin5
Sales-to-capital2.50
Beta0.95
Failure probability1.0%
Cost of capital (WACC)9.1%
Terminal WACC9.3%

Valuation bridge

PV of explicit FCFF13.18B
PV of terminal value13.36B
Equity value25.61B
÷ shares → per share$325.07

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 4.99B 9.5% 32.5% 1.30B 173.02M 1.12B 1.03B
2 5.44B 9.0% 32.9% 1.43B 180.32M 1.25B 1.05B
3 5.90B 8.6% 33.2% 1.57B 186.66M 1.38B 1.06B
4 6.38B 8.1% 33.6% 1.72B 191.85M 1.53B 1.08B
5 6.87B 7.7% 34.0% 1.87B 195.74M 1.67B 1.08B
6 7.37B 7.2% 34.0% 2.00B 198.15M 1.81B 1.07B
7 7.86B 6.8% 34.0% 2.14B 198.92M 1.94B 1.05B
8 8.36B 6.3% 34.0% 2.27B 197.93M 2.08B 1.03B
9 8.85B 5.8% 34.0% 2.41B 195.06M 2.21B 1.01B
10 9.32B 5.4% 34.0% 2.54B 190.22M 2.35B 979.51M
11 9.78B 4.9% 34.0% 2.66B 183.35M 2.48B 947.93M
12 10.22B 4.5% 34.0% 2.78B 174.43M 2.60B 913.38M
13 10.63B 4.0% 34.0% 2.89B 163.48M 2.73B 876.23M

Key risks

  • A sustained decline in vet clinic visits that erodes volume growth and pricing power
  • Competitive pressure from Zoetis, Antech/Mars and point-of-care entrants on instrument placements and consumables pricing
  • Multiple compression: at roughly 38x earnings, any growth deceleration reprices the stock sharply

Catalysts

  • Faster inVue Dx placements and Cancer Dx adoption that lift recurring revenue per clinic
  • A recovery in clinic visit volumes combined with continued 5-6% price realization

History

DatePriceIntrinsicMoSRating
2026-11-02$551.21 $325.07 -41.0% HOLD
2026-09-11$506.53 $142.25 -71.9% SELL
2026-07-23$545.00 $250.09 -54.1% HOLD
2026-06-23$541.31 $266.71 -50.7% HOLD